FI72428C - Framstaellningsfoerfarande foer ett stabilt, farmaceutiskt 8-metoxifuro-(3',2':6,7)-kumarinpreparat. - Google Patents
Framstaellningsfoerfarande foer ett stabilt, farmaceutiskt 8-metoxifuro-(3',2':6,7)-kumarinpreparat. Download PDFInfo
- Publication number
- FI72428C FI72428C FI801988A FI801988A FI72428C FI 72428 C FI72428 C FI 72428C FI 801988 A FI801988 A FI 801988A FI 801988 A FI801988 A FI 801988A FI 72428 C FI72428 C FI 72428C
- Authority
- FI
- Finland
- Prior art keywords
- preparation
- ester
- methoxalene
- active substance
- coumarin
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 16
- 229960000956 coumarin Drugs 0.000 title claims description 4
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 title claims 4
- 235000001671 coumarin Nutrition 0.000 title claims 2
- 239000002775 capsule Substances 0.000 claims description 21
- 239000000243 solution Substances 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 15
- 239000013543 active substance Substances 0.000 claims description 12
- 150000002148 esters Chemical class 0.000 claims description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 7
- 239000000194 fatty acid Substances 0.000 claims description 7
- 229930195729 fatty acid Natural products 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- -1 alkylene glycol Chemical compound 0.000 claims description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 150000004665 fatty acids Chemical class 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 239000000341 volatile oil Substances 0.000 claims description 3
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical class C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
- 239000003186 pharmaceutical solution Substances 0.000 claims description 2
- 229920000223 polyglycerol Polymers 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 239000000796 flavoring agent Substances 0.000 claims 1
- 235000013355 food flavoring agent Nutrition 0.000 claims 1
- 150000004670 unsaturated fatty acids Chemical group 0.000 claims 1
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical group C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 8
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 229940027035 oxsoralen Drugs 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 6
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 230000036765 blood level Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 229940074076 glycerol formal Drugs 0.000 description 3
- 150000002314 glycerols Chemical class 0.000 description 3
- 235000013773 glyceryl triacetate Nutrition 0.000 description 3
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 3
- 229960002622 triacetin Drugs 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 2
- 235000019477 peppermint oil Nutrition 0.000 description 2
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/92—Oral administration
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT444979A AT361116B (de) | 1979-06-25 | 1979-06-25 | Verfahren zur herstellung einer pharma- zeutischen zubereitung zur oralen verabreichung |
| AT444979 | 1979-06-25 | ||
| AT0221080A AT366573B (de) | 1980-04-24 | 1980-04-24 | Verfahren zur herstellung einer pharmazeutischen zubereitung |
| AT221080 | 1980-04-24 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI801988A7 FI801988A7 (fi) | 1980-12-26 |
| FI72428B FI72428B (fi) | 1987-02-27 |
| FI72428C true FI72428C (fi) | 1987-06-08 |
Family
ID=25597954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI801988A FI72428C (fi) | 1979-06-25 | 1980-06-19 | Framstaellningsfoerfarande foer ett stabilt, farmaceutiskt 8-metoxifuro-(3',2':6,7)-kumarinpreparat. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4913901A (enExample) |
| DE (1) | DE3023109A1 (enExample) |
| FI (1) | FI72428C (enExample) |
| FR (1) | FR2459658A1 (enExample) |
| GB (1) | GB2052980B (enExample) |
| NO (1) | NO153951C (enExample) |
| SE (1) | SE445422B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1173751A (en) * | 1980-05-07 | 1984-09-04 | Jack H. Lazarus | Methoxsalen dosage forms |
| US5096887A (en) * | 1984-03-01 | 1992-03-17 | Lamorna Investments Proprietary Limited | Treatment of high protein oedemas |
| WO1985003864A1 (en) * | 1984-03-01 | 1985-09-12 | Casley Smith John Royle | Treatment of high protein oedemas by direct application of benzo-pyrones |
| LU85829A1 (fr) * | 1985-04-01 | 1986-11-05 | Cird | Composition pour bains a base de psoralene dans le traitement du psoriasis |
| US4999375A (en) * | 1989-04-11 | 1991-03-12 | Hoffmann-La Roche Inc. | Psoralen reagent compositions for extracorporeal treatment of blood |
| GB2318291B (en) * | 1996-10-15 | 1998-09-23 | Robin Morley | 8-Methoxypsoralen containing additives for topical application in bath water |
| HK1043019B (zh) | 1998-10-08 | 2005-05-13 | 高新研究公司 | 用於预防和治疗原虫病的组合物和方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2406444A1 (fr) * | 1977-10-21 | 1979-05-18 | Goupil Jean Jacques | Nouveau medicament contenant un derive du psoralene |
| US4130568A (en) * | 1976-09-14 | 1978-12-19 | Hoffmann-La Roche Inc. | 8-Methoxypsoralen derivatives |
| US4454152A (en) * | 1980-05-07 | 1984-06-12 | Hoffmann-La Roche Inc. | Methoxsalen dosage forms |
-
1980
- 1980-06-12 SE SE8004383A patent/SE445422B/sv not_active IP Right Cessation
- 1980-06-13 NO NO801759A patent/NO153951C/no unknown
- 1980-06-18 FR FR8013490A patent/FR2459658A1/fr active Granted
- 1980-06-19 FI FI801988A patent/FI72428C/fi not_active IP Right Cessation
- 1980-06-20 DE DE19803023109 patent/DE3023109A1/de active Granted
- 1980-06-23 GB GB8020457A patent/GB2052980B/en not_active Expired
-
1984
- 1984-03-28 US US06/594,060 patent/US4913901A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| GB2052980B (en) | 1983-12-14 |
| SE445422B (sv) | 1986-06-23 |
| FR2459658B1 (enExample) | 1984-04-27 |
| FR2459658A1 (fr) | 1981-01-16 |
| NO153951B (no) | 1986-03-17 |
| DE3023109A1 (de) | 1981-01-08 |
| SE8004383L (sv) | 1980-12-26 |
| FI801988A7 (fi) | 1980-12-26 |
| GB2052980A (en) | 1981-02-04 |
| FI72428B (fi) | 1987-02-27 |
| NO153951C (no) | 1986-06-25 |
| NO801759L (no) | 1980-12-29 |
| US4913901A (en) | 1990-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Frölich et al. | Indomethacin increases plasma lithium. | |
| EP0221176B1 (en) | Pharmaceutical vehicles for recucing transdermal flux | |
| DE60028384T2 (de) | Propofol enthaltende anästhetische zusammensetzung zur intravenösen injektion | |
| DE69425859T2 (de) | Cyclosporin enthaltende Weichkapsel | |
| EP0712631A2 (en) | Cyclosporin containing multiple emulsions | |
| JP2012006931A (ja) | 疎水性治療剤の改善された送達のための組成物および方法 | |
| KR100471680B1 (ko) | 사이클로스포린제제 | |
| EA013744B1 (ru) | Фармацевтические композиции на основе нейроактивного стероида и их применение | |
| JPS61275215A (ja) | バイオアベイラビリテイが増大したｎ−（４−ヒドロキシフエニル）レチンアミド製剤 | |
| EP0512109B1 (en) | Oral pharmaceutical composition containing cyclosporin and process for preparing same | |
| FI72428C (fi) | Framstaellningsfoerfarande foer ett stabilt, farmaceutiskt 8-metoxifuro-(3',2':6,7)-kumarinpreparat. | |
| EP0274714A1 (en) | Topical preparation containing ofloxacin | |
| EP0722719B1 (de) | Verfahren zur Herstellung von Flavano-Lignan-Zubereitungen | |
| CZ272995A3 (en) | Pharmaceutical preparation for oral administration | |
| EP0025696B1 (en) | Controlled release parasiticidal formulations | |
| AU2021206858B2 (en) | Isotretinoin formulations and uses and methods thereof | |
| UA57725C2 (uk) | Композиція, що містить циклоспорин, спосіб одержання желатинових капсул, що містять циклоспорин, та спосіб лікування станів чи симптомів з його використанням | |
| EP0896819A1 (en) | Antiglucocorticoid drug | |
| EP0521057A1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING IPRIFLAVONE, PROCESS FOR THE PREPARATION AND PHARMACEUTICAL USES OF THESE COMPOSITIONS. | |
| CN101601652A (zh) | 糠酸莫米松脂质体乳膏 | |
| KR20250013306A (ko) | 페오놀 및 아포시닌을 포함하는 액체 제형 | |
| US4046919A (en) | Treatment of cells | |
| DE102013107024A1 (de) | Methoden und Zusammensetzungen zum Behandeln, Modifizieren und Handhaben von Knochenkrebsschmerz | |
| JPH0140808B2 (enExample) | ||
| Goracinova et al. | Midazolam-sirupus, formulation and pharmacodynamic efficacy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MA | Patent expired |
Owner name: GEROT PHARMAZEUTIKA GESELLSCHAFT M.B.H |